Category Archives: India Globalization Capital, Inc. IGC

QualityStocksNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Becomes Exclusive Licensee of Cannabis-Based Treatment for Alzheimer’s Disease

June 12, 2017

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced its entry into a definitive license agreement with the University of South Florida that makes the company the exclusive licensee of the U.S. patent filing entitled ‘THC as a Potential Therapeutic Agent for Alzheimer’s Disease’. If the patent filing is granted and proven, IGC anticipates that it could create a “significant therapeutic pathway” in the Alzheimer’s disease market, which is expected to record direct costs in excess of $450 billion annually in the next 12 years. “Securing this licensing agreement from the University of South Florida represents a major turning point for IGC as we now look to prepare several of our key products for clinical trials,” Ram Mukunda, CEO of IGC, stated in the news release. “We have worked hard to assemble a strong development team and a primary pipeline of four major products addressing large markets and possible blockbuster indications utilizing cannabis-based therapies. We are putting the finishing touches on our products, which may include filing additional patents, and we very much expect to start pursuing clinical trials for our Alzheimer’s product and others this year.”

To view the full press release, visit http://dtn.fm/Zwr6R

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

About IGC

India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland. For more information visit www.igcinc.us

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Pursues Clinical Trials of Cannabis-Based Combination Therapies with Assistance of New Advisor

June 7, 2017

India Globalization Capital (NYSE MKT: IGC) recently named Craig Cheifetz, M.D. as an advisor to assist the company with its clinical trials in microbiology, immunology, neuroscience and biotechnology. IGC CEO Ram Mukunda stated in a news release that the company looks forward to Dr. Cheifetz’s contributions as IGC moves forward in the development of unique cannabis combination therapies. “The company anticipates clinical trials in 2017 for several indications, including pain, a huge market. IGC has already filed for six patents in areas such as eating disorders and epilepsy, in addition to pain. It is working on several more filings for indications including depression, Alzheimer’s and Parkinson’s disease. Its lead candidate is IGC-501, and it has filed patents for the candidate in the United States, Canada and Europe.”

To view the full article, visit http://dtn.fm/Yn07f

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

About India Globalization Capital, Inc.

India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland.

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

India Globalization Capital, Inc. (NYSE: IGC) Targets Human and Veterinary Epilepsy with Innovative Cannabinoid Therapy

June 6, 2017

With about 50 million people affected worldwide, drug-resistant epilepsy, or refractory epilepsy, is a very serious condition for which a medical solution has not yet been found, but the therapeutic benefits of phytocannabinoid-based therapies for seizures have been coming under increased scrutiny lately. There is mounting evidence that cannabinoid extracts, and in particular cannabidiol (CBD), can have a positive impact on epilepsy patients and alleviate seizures, as indicated by recent research. Companies such as India Globalization Capital, Inc. (NYSE MKT: IGC) are at the forefront of discovering cannabinoid-based epilepsy treatments for humans and animals alike, by developing innovative formulations that can change the paradigm of seizure therapies.

Although stories of cannabis benefits for seizure patients have been around for more than a century, the interest in marijuana has increased significantly in the last few years due to the growing legalization movement. At the moment, marijuana is legal for medical or recreational consumption in almost 30 states, and supporters of legalization hope the substance will eventually be allowed nationwide. There is also hope that widespread legalization will eventually force the federal government to declassify marijuana as a Schedule I drug, a classification that currently stands in the way of the cannabis industry’s potential development mostly by limiting businesses’ access to banking and financial solutions.

Most research into the effects of cannabis on epilepsy has focused on CBD, the most abundant non-psychoactive cannabinoid in the marijuana plant. According to the American Epilepsy Society (http://dtn.fm/6bMxP), recent studies have indicated that CBD was successfully used to reduce the intensity and frequency of seizures in children with refractory epilepsy. Multiple other studies have indicated similar results, in particular a dramatic drop in the number of seizures reported by patients who were given CBD-based treatments, according to the Epilepsy Foundation (http://dtn.fm/cxG3P). The same effects were reported for CBD use to treat veterinary epilepsy in multiple species, most notably in cats and dogs. The second most abundant cannabinoid extract, tetrahydrocannabinol (THC), was also found to have a positive impact on epilepsy patients, but it is not as easily tolerated due to its psychotropic properties.

Maryland-based IGC is developing innovative CBD-based therapies targeting both human and veterinary epilepsy, as well as other types of seizures. The company has already filed for a U.S. patent for the formulation, administered via different delivery technologies, and has plans to start metabolic profiling and apply to the Food and Drug Administration to start clinical trials. One of its product candidates targeting seizures in animals, IGC-502, is scheduled to begin clinical trials this year.

In addition to seizures, IGC has developed a pipeline of cannabinoid-based therapies targeting various major disorders, including eating disorders and neuropathic pain. The company is becoming a leader in the use of combination therapies that pair cannabis extracts with other traditional medications for the treatment of different conditions, positioning itself as a unique and interesting investment option on the ever-growing medical marijuana market.

For more information, visit the company’s website at www.IGCinc.us

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

India Globalization Capital, Inc. (NYSE: IGC) Taps Dr. Craig Cheifetz as Advisor for Clinical Trials of Cannabis-Based Combination Therapies

May 24, 2017

India Globalization Capital, Inc. (NYSE MKT: IGC) has named Craig Cheifetz, M.D., as an advisor to aid the company in its clinical trials in microbiology, immunology, neuroscience, and biotechnology. IGC is engaged in the development of cannabis-based therapies, which treat pain, terminal neurological and oncological diagnosis, PTSD, seizures, and other life altering issues. The company, based in Bethesda, Maryland, has a portfolio of patent filings for its phytocannabinoid-based treatments.

In a news release, Ram Mukunda, CEO of IGC, welcomed Cheifetz to the company’s advisory team, noting that he looks forward to Chiefetz’s contributions as IGC develops unique cannabis combination therapies.

Cheifetz is the Medical Director of Inova VIP 360, Northern Virginia’s Concierge Medicine Program. He is also Regional Dean at Virginia Commonwealth University Inova Fairfax Campus.

He received his M.D. from the State University of New York at Buffalo and also attended Georgetown University, where he trained in internal medicine. He was National GRMC Chairman from 2011 to 2013.

“We remain committed to accelerating our initiatives and building robust a portfolio of compounds to address large market conditions,” Mukunda noted in the release.

The company anticipates clinical trials in 2017 for several indications, including pain, a huge market. IGC has already filed for six patents in areas such as eating disorders and epilepsy, in addition to pain. It is working on several more filings for indications including depression, Alzheimer’s and Parkinson’s disease. Its lead candidate is IGC-501, and it has filed patents for the candidate in the United States, Canada and Europe.

For more information, visit the company’s website at www.IGCinc.us

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

India Globalization Capital, Inc. (NYSE: IGC) Developing Phytocannabinoid-Based Product Pipeline to Treat Two- and Four-Legged Alike

May 22, 2017

Looking to gain an advantageous foothold in the burgeoning medical marijuana market, India Globalization Capital, Inc. (NYSE MKT: IGC) is developing innovative cannabis-based combination therapies that have application for both humans and animals. The company’s focus is on treating pain, post-traumatic stress disorder (PTSD), chronic and terminal neurological and oncological diagnoses, cachexia, and other life-altering medical conditions.

IGC continues developing a portfolio of patent filings for phytocannabinoid-based treatments and has filed six patents to date. The company currently has three products in pre-clinical trials: IGC-501 for treatment of neuropathic pain in adult humans, IGC-502 for treatment of seizures in animals, and IGC-504 for treatment of cachexia in humans and animals.

Two of IGC’s patent filings, IGC-502 and IGC-505, are for combination therapies to treat seizures in dogs and cats, which represents a remarkably large market. Statistics show that between one percent and over five percent of dogs in the United States have some kind of seizure disorder. Certain dog breeds with hereditary epilepsy may have up to 15-20 percent incidence of seizures.

IGC’s novel therapy uses cannabinoid extracts in combination with other drugs to treat seizures in both dogs and cats, and this therapy has potential for application in humans, as well. The therapy can be administered through a variety of delivery technologies.

Operating on the belief that expanding cannabis legalization will create explosive demand for cannabinoid-based pharmaceutical therapies and related technologies and services, IGC is racing to be at the head of the pack and to be a first mover in the marijuana space by developing novel therapies, filing patent applications, and acquiring technologies from related industries that can cross over to cannabis as soon as permitted by federal law.

The company largely employs an outsourced model and has formed strategic alliances with doctors and scientists with expertise in central and peripheral nervous system disorders, the FDA process, and in pharmaceutical, nutraceutical and veterinarian trials. IGC also continues seeking information exchanges with medical cannabis dispensaries, doctors, research scientists, biotech companies, and medical and business professionals within the cannabinoid space, placing great value on collaborative research that can aid in the commercialization of products and in locating new ways to help patients — both human and animal — benefit from cannabinoids.

For more information, visit the company’s website at www.IGCinc.us

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

India Globalization Capital, Inc. (NYSE: IGC) is Blazing a Trail with its Cannabis Plus Therapies

May 18, 2017

Slowly but surely cannabis is losing the stigma that has plagued it for close to one hundred years. Even some who frown on its use for recreational purposes are willing to consider that there may be therapeutic benefits in extracts of the cannabis sativa plant and so, increasingly, cannabinoids are being investigated to determine their effectiveness to treat a variety of debilitating medical conditions. Cannabinoid pharma is emerging as an entirely new industry segment in pharmaceuticals, and, as it does so, one innovative research company is blazing a trail in this new market by creating a niche of its own. India Globalization Capital, Inc. (NYSE MKT: IGC) has created its own space in pharmaceuticals. The Bethesda, Maryland-based company is a first mover in “combination therapies” that merge cannabinoids with existing drugs to provide more effective remedies.

IGC is not only a first mover in combination therapies; the company is also a fast mover. To date, IGC has dispatched six provisional patent filings to the U.S. Patent and Trademark Office for the indications of pain, medical refractory epilepsy, seizures, cachexia and eating disorders. Together, the remedies for these conditions present huge market opportunity, and IGC’s current low valuation versus comparable cannabis companies represents an important alert for all investors in this burgeoning industry.

IGC-501 is being developed to combat pain. The pain market represents a significant component of the health care system, with The Journal of Pain reporting in September 2012 that the annual estimated national cost of pain ranges from $560 billion to $635 billion, a figure that exceeds the cost of treating all other priority health conditions. Also, a NetworkNewsWire report on data released by Transparency Market Research estimates the global pain management therapeutics market will have a 3.7 percent CAGR through 2024, to reach $83.0 billion (http://dtn.fm/cMh1z).

Chronic pain takes such an exacting toll on the nation’s health that the American Pain Society has recommended pain be characterized as a fifth ‘vital sign’, along with body temperature, pulse rate, respiratory rate and blood pressure. Pain treatment can save lives. Terminal illnesses are often accompanied by levels of pain so intense and difficult to treat that death seems preferable. In addition, arthritis has been particularly problematic for women, according to the Arthritis Foundation, which reports that since 1999 there has been a 22 percent increase in the number of women who attribute their disability to arthritis.

As awareness of the effects of chronic pain has grown, increasingly powerful drugs such as morphine, codeine, and hydrocodone are being prescribed. However, these opioids are treacherously addictive and their use is often subverted from pain relief, making their way into recreational use. According to the Centers for Disease Control (CDC), 29,000 Americans die every year from opioid-related overdoses. This alarming statistic shows the pressing need for less addictive analgesics like IGC-501.

IGC-503 tackles refractory epilepsy, which affects about 50 million in the U.S. alone. Refractory epilepsy refers to cases of epilepsy that are unresponsive to current medications. Also in the pipeline is IGC-504, intended for those who suffer from cachexia, known as wasting syndrome. About 1.3 million in the U.S. experience cachexia associated with cancer, multiple sclerosis (MS), Parkinson’s, HIV/AIDS and other devastating maladies. In addition, there is IGC-506, designed to combat eating disorders, which are said to affect about 30 million Americans (http://dtn.fm/2j6Pq). Two other patents, IGC-502 and IGC-505, are designed to treat epileptic seizures in dogs and cats.

On the release of its financial results for the third-quarter ended December 31, 2016, CEO Ram Mukunda stated, “In 2017, our goal is to accelerate the development of our cannabis-based therapy portfolio to support key indications such as pain, seizures, cachexia, PTSD, and depression. In tandem, we expect to initiate pre-clinical trials on IGC-501-pain, IGC-502-seizures and IGC-504-cachexia.”

For more information, visit the company’s website at www.IGCinc.us

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

QualityStocksNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Adds Craig Cheifetz, M.D. to Advisory Team

May 16, 2017

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that Craig Cheifetz, M.D. has joined the company as an advisor to provide guidance on clinical trials, biotechnology, neuroscience, immunology and microbiology. “I welcome Dr. Cheifetz to the IGC advisory team and look forward to his contributions as we move forward in developing cannabis-based, combination therapies,” Ram Mukunda, CEO of IGC, stated in the news release. “We remain committed to accelerating our initiatives and building a robust portfolio of compounds to address large market conditions.” Cheifetz currently serves as Regional Dean at Virginia Commonwealth University Inova Fairfax Campus and Medical Director of Inova VIP 360, North Virginia’s premier concierge medicine program. He received his M.D. from the State University of New York College at Buffalo and trained in Internal Medicine at Georgetown University.

To view the full press release, visit http://dtn.fm/4kxKk

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

About IGC

India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland. For more information visit www.igcinc.us

India Globalization Capital, Inc. (NYSE: IGC) Positioned to Lead in Phytocannabinoid Pharmaceuticals

May 8, 2017

A study recently highlighted by the American Epilepsy Society (AES) at its 70th annual meeting focused on the potential of cannabidiol (CBD), a derivative of the cannabis plant, as a promising treatment for reducing both the frequency and severity of seizures in children with drug resistant epilepsies (http://dtn.fm/4uYeH). According to the study, patients who received CBD treatment exhibited over 45 percent mean reduction in seizures, and researchers were outspoken in support of further research.

Cannabidiol is the most abundant non-psychoactive cannabinoid found in the cannabis plant. Both anecdotal evidence and pre-clinical research have suggested that CBD may have a broad range of beneficial therapeutic uses in humans and animals including pain mitigation, epileptic seizures and wasting disease eating disorders (cachexia). Animal studies have also shown promise for CBD’s anticonvulsant efficacy in multiple species (http://dtn.fm/Cusv2).

As referenced in a recent article (http://dtn.fm/QB8Kv), multiple companies compete in the $65 billion diverse pet product market, with about $15 billion spent on veterinary care annually in the United States. Seizures afflict about five percent of the 90 million dogs in the U.S. and a little over two percent of the 94 million felines. The most commonly used drugs to treat pet seizures include a lifetime regimen of phenobarbital, potassium bromide, and diazepam. India Globalization Capital, Inc. (NYSE MKT: IGC) is changing the paradigm of seizure treatments for dogs and cats based on its novel patent pending therapy using cannabinoid extracts.

India Globalization Capital is actually building a broad portfolio of multiple intellectual properties around the utilization of phytocannabinoid-based therapies in both animals and humans. The company is at the forefront of the combined use of cannabis-based extracts with other medications to reduce side effects and to increase bioavailability and absorption (phytocannabinoid-based combination therapy).

IGC has developed a pipeline of patent pending cannabinoid-based drugs targeting large market disorders such as therapeutics for neuropathic pain, human and animal seizures, refractory epilepsy and eating disorders. Several of these therapeutic compounds are scheduled for pre-clinical trials this year. With a team of experts encompassing patent law, clinical trials and regulatory procedures, IGC is positioned to become a leader in specialty pharmaceuticals and offers an interesting opportunity to profit from this exciting new market.

For more information, visit the company’s website at www.IGCinc.us

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

India Globalization Capital, Inc. (NYSE: IGC) Engages a Critical Point in Cannabis History

May 5, 2017

Cannabis is now legal medically or recreationally in 28 states in the U.S., and companies such as India Globalization Capital, Inc. (NYSE MKT: IGC) are developing revolutionary cannabinoid-based combination pharmaceutical therapies. Cannabis’ history doesn’t begin in the 1960s. Scientists have dated burned cannabis seeds found in Siberia to 3,000 B.C., and mummified psychoactive marijuana has been found in tombs of individuals buried around 2,500 B.C. Fast forward a few thousand years and add laws, regulations, and cultural stigma, and behold one of the most disputed substances. In the 1850s, recreational cannabis was considered fashionable in the U.S., and it was widespread in the 1920s as well. In 1937, Congress passed the Marijuana Tax Act, making it illegal to possess and transfer cannabis. The Controlled Substances Act (CSA), passed in 1970, lists cannabis as a high-abuse-potential Schedule 1 drug.

Although the CSA hasn’t been changed, marijuana has been decriminalized in many places. Medical cannabis was legalized in California in 1996, and Alaska, Oregon, Washington, and Arizona followed suit in 1998. The trend has accelerated, and, by 2011, additional states were favoring medical cannabis or passed legislation to decriminalize it. These included Nevada, Colorado, Massachusetts, New Jersey, Connecticut, and Washington D.C. Even more impressive than the territory covered by jurisdictions allowing cannabis and cannabis-related products is the multi-billion-dollar industry that’s emerged and promises to keep on growing.

Ram Mukunda, executive chairman, CEO, and president of India Globalization Capital, has taken the company on a course that is as impressive as the cannabis industry itself. IGC was founded in 2005 to mine iron ore. Once the prices for iron ore plummeted, Mukunda took the company in a different direction to focus on the untapped potential of cannabinoids and cannabis-based extracts.

Today, the company’s pipeline of patent-pending cannabinoid-based compounds represents treatment for a number of large market conditions. Cannabis-based pain medications are in development, providing opportunities for investors, as are drugs for post-traumatic stress disorder, Alzheimer’s disease, Parkinson’s disease, and depression. Therapeutic drugs for treating seizures in humans and animals are in development as well.

The company’s drug development pipeline consists of a cream/patch for treating neuropathic pain, eating disorder treatments for adult and veterinary use, and a refractory epilepsy drug for adults. Pre-clinical trials are anticipated in 2017 for three of IGC’s combination therapy compounds. The company has come a long way from running mining operations to developing high potential phytocannabinoid-based treatments, but it is now helping to shape a critical point in cannabis history as medical use becomes more mainstream.

To learn more about India Globalization Capital, Inc., its drug development pipeline, and other cannabinoid- and cannabis-related initiatives, visit the company online at www.IGCinc.us

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

India Globalization Capital (NYSE: IGC) Strategically Staking Claims in the Medical Marijuana Markets

May 4, 2017

In a testament to its medical efficacy, 29 states and the District of Columbia have now legalized medical marijuana. This groundswell with state sanction and now widespread public acceptance has started a stampede of companies jockeying to profit from legalization. From the sale of oils and extracts to specialized cultivation, multiple companies are rushing into this new market hoping to cash in on surging demand. However, rushing in just might not be the right approach to making real money in this sector.

There’s an old adage that says the way to create real wealth is to find out where everyone is going, get there first and buy real estate. Utilizing a strikingly similar approach, one interesting company is strategically staking claims to medicinal marijuana territory. India Globalization Capital (NYSE MKT: IGC) formerly mined and converted low-grade iron ore to high-grade ore until prices plummeted. It was then that company management made the decision that to preserve shareholder value it must change course. As a result, IGC entered the burgeoning medical marijuana market. It’s estimated that sales in the cannabidiol (CBD) market, the medicinal non-euphoric part of cannabis, will grow 700 percent to nearly $3 billion annually by 2020. That kind of explosive growth is certain to attract multiple pretenders to the throne.

With decades of Wall Street experience, IGC management knew better than to just rush into the feeding frenzy. Instead, the company took a deliberate, judicious approach to market opportunity. Realizing that therapeutic cannabidiol treatments essentially comprised new drug formulations, IGC assembled a team of highly skilled physicians and researchers to compare anecdotal efficacy with scientific evidence and identify areas where cannabidiol therapies could have significant impact in large market maladies. The company then engaged experienced pharmaceutical patent attorneys to protect these new intellectual properties and now has a pipeline of patent pending cannabinoid-based drugs to treat neuropathic pain, human and animal seizures, refractory epilepsy, and eating disorders. Several of these novel therapeutics are scheduled for pre-clinical trials this year.

Focused on expanding its patent portfolio in the CBD space, India Globalization Capital is among the very first to stake claims in cannabis-based combination therapies. The company has been building intellectual properties surrounding the combined use of cannabis-based extracts with other medications to reduce side effects and to increase bioavailability and absorption. To further its reach, IGC also intends to take equity positions in ancillary cannabis businesses and is aggressively seeking partnerships with other scientifically based cannabinoid researchers, as well as with producers and processors holding intellectual properties in particular cannabidiol strains that can be proved up for pharmacological use.

With its scientific approach to new drug formulation protected with multiple patents, IGC is strategically staking out incredibly valuable territory in the new frontier of cannabidiol therapeutics. The company’s expanding IP portfolio and low market capitalization present a compelling investment opportunity in the CBD space. As curative phytocannabinoid treatments expand exponentially, India Globalization Capital is well positioned to reap substantial rewards for getting there early and owning patent protected turf in the medicinal marijuana sector.

For more information, visit the company’s website at www.IGCinc.us

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

India Globalization Capital, Inc. (NYSE: IGC) is a First Mover in Cannabinoid Combination Therapies

April 24, 2017

The success of the Walkman back in the 1980s is testament to the power of getting to market first. By some accounts, Sony sold over 200 million units of its innovative portable cassette player (http://dtn.fm/CV8Et). Now, India Globalization Capital, Inc. (NYSE MKT: IGC) is taking a leaf from the Sony playbook. This pioneering company is a ‘first mover’ in the cannabinoid combination therapy space. IGC is developing a portfolio of products that use cannabinoids in conjunction with existing drugs to tackle chronic pain and a variety of other debilitating medical conditions.

Chronic pain from a range of ailments plagues millions around the world, and many of the analgesics employed to treat it, such as morphine, codeine, and hydrocodone, are opioids. However, opioids are notoriously addictive and their use is often subverted from pain relief. Used as recreational drugs, ‘opioid addiction is America’s 50-state epidemic’, the New York Times has reported (http://dtn.fm/YcgB8), with an effect that is fatal in many instances. According to the Centers for Disease Control (CDC), 29,000 Americans die every year from opioid-related overdoses. In light of these frightening developments, there is a growing imperative for less addictive anodynes.

The time is right. Results, published on Monday, April 17, of a Yahoo/Marist poll (http://dtn.fm/mKg7o) show that the public is not only becoming more apprehensive about opioids, but is warming to the use of cannabinoids to treat pain. ‘Two-thirds of the respondents in the telephone survey said opioid drugs such as Vicodin or OxyContin are “riskier” to use than pot, even when the pain pills are prescribed by a doctor.’ They will be happy to hear that IGC is coming to the rescue. The company has filed a patent for IGC-501, a cannabis-based formulation that addresses neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. IGC expects to begin pre-clinical trials for IGC-501 this year. Since approximately 80 percent of the global opioid supply is consumed in the United States, this presents a domestic market opportunity estimated at about $25 billion.

IGC-501, with its potential to replace treacherously addictive opioids, is not all that IGC has up its sleeve. The company has a robust portfolio of five other combination drug candidates with both human and veterinary applications. It has filed two patents, IGC-502 and IGC-505, for the treatment of seizures in dogs and cats. Most animal seizures stem from epilepsy, which is more common in dogs and cats than formerly recognized. About five percent of dogs and about one percent of cats are epileptic.

It also has IGC-503, aimed at refractory epilepsy, a term that’s used to describe cases of epilepsy that are unresponsive to current medications. Refractory epilepsy affects about 50 million in the U.S. alone. In the pipeline as well is IGC-504, intended for those who suffer from cachexia, known as wasting syndrome. About 1.3 million in the U.S. experience cachexia associated with cancer, multiple sclerosis (MS), Parkinson’s, HIV/AIDS and other devastating maladies. In addition, there is IGC-506, designed to combat eating disorders, which are said to affect about 30 million Americans (http://dtn.fm/d1SEs).

IGC is out to save the world, it seems. Earlier this month, the company announced it had filed patent applications for IGC-501 in Canada, Israel and Europe in support of its ongoing cannabis-based combination therapy development initiatives.

“In 2017, our goal is to accelerate the development of our cannabis-based therapy portfolio to support key indications such as pain, seizures, cachexia, PTSD, and depression. In tandem, we expect to initiate pre-clinical trials on IGC-501-pain, IGC-502-seizures and IGC-504-cachexia,” CEO Ram Mukunda stated in a news release.

That is welcome news to the many millions who suffer daily from these conditions.

For more information, visit the company’s website at www.IGCinc.us

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

India Globalization Capital, Inc. (NYSE: IGC) Plans to Develop Cannabinoid Extract Therapies for Cats and Dogs

April 13, 2017

India Globalization Capital, Inc. (NYSE MKT: IGC) intends to become a “first-mover” in developing cannabis-based combination therapies for large market conditions such as pain, eating disorders, refractory epilepsy, and seizures. In addition, IGC has filed two patents, IGC-502 and IGC-505, for combination therapies for the treatment of seizures in dogs and cats, which in it itself is a surprisingly large market.

It is believed that abnormal brain activity is the cause of most seizures in dogs and cats. These seizures can be either violent or subtle. Some seizures may occur just once, but others can be repeated and require treatment before affecting larger parts of the brain.

The pet market is large and growing. According to research by the American Pet Products Association (http://dtn.fm/iiO30), the market in 2017 is expected to reach $16.62 billion for veterinary care and $14.93 billion for supplies and over-the-counter medicine. By far, dogs and cats are the most popular pets. In a 2017 survey by National Pet Owners, 60.2 million American households owned a dog and 47.1 million households owned a cat.

While some of this research may also be beneficial for treating humans, it reflects IGC’s targeting of the larger veterinary market. In dogs, primary epilepsy — or idiopathic epilepsy — occurs in about 5% of the canine population (http://dtn.fm/pRtJ3), most often in dogs between the ages of six months and six years. In cats, seizures are much less common, occurring in only 0.5-1.0% of the population. Most are intracranial, stemming from the brain, and are epileptic in nature.

Hemp-based products for dogs, especially for older and pain-ridden dogs, are in a gray market. However, the market potential is great (http://dtn.fm/b1DMo), because it sits at the current intersection of medical pharmaceutical marijuana and pet care. Veterinarians acknowledge that legal restrictions currently impede distribution of these products in the U.S., but advances in legalization of medical marijuana may be helpful in changing the environment. For now, IGC is researching the potential of cannabis-based treatments in the pet market and developing products as this potentially represents a significant future opportunity.

For more information, visit the company’s website at www.IGCinc.us

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

India Globalization Capital, Inc. (NYSE: IGC) at the Forefront of Innovation Thanks to Strategic Alliances

April 7, 2017

How does a company in the mining industry successfully move toward becoming a leader in the marijuana sector, specifically cannabinoid-based pharmaceutical therapies that treat a variety of diseases and conditions? In the case of India Globalization Capital, Inc. (NYSE MKT: IGC), the answer is creative management’s ability to identify opportunity, coupled with a relentless drive toward innovation.

IGC made its switch to the marijuana industry after its CEO, Executive Chairman, and President Ram Mukunda was unafraid to recognize and act on a need for the company to make a positive and swift switch to a stronger and more lucrative market. This led IGC to cannabis and, in particular, phytocannabinoids.

The cannabis plant has a number of subspecies, some of which have psychoactive properties and others do not. Cannabis sativa is psychoactive, while other forms, such as Cannabis Sativa L., or hemp, and Cannabis ruderalis, are not. In fact, the latter offer high levels of cannabidiol, which is most commonly used on a medical level.

Legal marijuana is now becoming one of the fastest growing industries in the United States, expected to create just under 300,000 jobs for Americans by 2020 (http://dtn.fm/fEq5E), and an increasing number of states are legalizing the drug both medically and recreationally, with the potential for further legalization on the horizon.

Although the marijuana industry is growing at an exponential rate, federal laws that classify marijuana as a Schedule 1 drug make it hard for businesses to reach their full potential,but IGC has been able to research and take advantage of cannabinoids, since these are not illegal. Part of IGC’s success is due to the fact that the company is not going about its mission to help patients suffering from pain, PTSD, seizures, and many other diseases on its own. The company is creating strategic alliances with doctors, researchers, dispensaries, and practitioners, among other industry experts, in order to develop a product portfolio of much needed phytocannabinoid-based therapies.

IGC has entered into the industry aware that there is a huge amount of information already available at the grassroots level of the marijuana industry. This is why it is seeking IP transfers with producers who know about growing hybrids and strains that are rich in specific phytocannabinoids that can be used in a pharmaceutical environment to help patients who could benefit from cannabinoids.

In addition to its extensive development pipeline, which includes six products for various disorders in both adults and animals and three expected to go through to preclinical trials this year, IGC is planning on taking equity positions within companies that are directly and indirectly part of the marijuana industry, another way that investors can take advantage of a booming industry.

For more information, visit the company’s website at www.IGCinc.us

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

India Globalization Capital, Inc. (NYSE: IGC) From Mining to Marijuana

March 31, 2017

At first blush, India Globalization Capital (NYSE: IGC) would seem a curiosity clothed in an enigma. Just how does a NYSE company move from a successful mining orientation to a pioneer in the development of multiple cannabinoid-based pharmaceutical therapies to treat pain and disease? The enigma can be disrobed by looking at the tenacity and vision of its management.

Ram Mukunda has served as Executive Chairman, CEO and President of India Global since inception in 2005. He holds distinguished mathematics and engineering degrees and worked in multiple Wall Street positions for more than 25 years, serving communications firms such as Intelsat SA and Startec. Mukunda actually founded Startec in 1991 to provide VOIP service to emerging economies. As Chairman and CEO of Startec, he led the company to a $60 million public stock offering in 1997. His introduction to the mining industry came a few years later through a company he co-founded, India Globalization Capital. The company mined and converted low-grade iron ore to high-grade ore. Iron ore prices subsequently plummeted nearly 75 percent, putting it below the cost of production. That’s when Mukunda made a difficult decision and charted a course change for the company.

Realizing that the lucrative mining business was bust, he searched for a growth arena to position the company and move forward. He ultimately centered on the burgeoning cannabis industry and the myriad of potential medical benefits. Mukunda and his team realized that there were a lot of untapped uses for cannabinoids and cannabis-based extracts. They recruited a team of highly skilled doctors and patent attorneys, comparing anecdotal stories with scientific evidence and identifying areas where patents had not been filed. This process has yielded results.

The company now has a pipeline of patent pending cannabinoid-based drugs targeting large market maladies, which includes therapeutics for neuropathic pain, human and animal seizures, refractory epilepsy and eating disorders. Several of these therapeutic drugs are scheduled for pre-clinical trials this year. The company is transitioning fast from building research teams and developing a patent portfolio to marketable products.

For the past few years, India Globalization Capital has also focused interest on cannabis-based combination therapies, using cannabis-based extracts in combination with other medications to reduce side effects and increase bioavailability and absorption. As one of the first to enter this space, the company has been building intellectual property around these precepts and expects to reap substantial rewards from this arena.

From mining to medical marijuana would seem an incredible leap, but, when looking at India Global and the leadership of Ram Mukunda, it would be tough to bet against a leader with such tenacity and vision. And with a $12MM market cap, IGC is quite compelling given the valuations attributed to its peers.

For more information, visit the company’s website at www.IGCinc.us

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

India Globalization Capital, Inc. (NYSE: IGC) Aims to Become a Leading Provider of Cannabis-Based Combination Therapies

March 28, 2017

India Globalization Capital, Inc. (NYSE MKT: IGC) has set a long-term goal for itself in the U.S. of becoming a leading provider of cannabis-based pharmaceutical and nutraceutical products. This is a transition away from its earlier short-term strategy, including the sale of electronics and development of a hotel site in Malaysia. To this end, the company has jettisoned its electronics business. IGC is now fully focused on building a portfolio of patents and starting clinical and pre-clinical trials for a series of pain-reducing and other cannabis-based therapies. These therapies are designed to treat neuropathic pain, seizures, Parkinson’s, anorexia/cachexia, Alzheimer’s, and PTSD.

Ram Mukunda, CEO of the company, indicated that IGC’s 2017 goals are focused on its progression toward commencement of clinical trials for these combination therapies. The Journal of Pain, in September 2012, reported that between $560 billion and $635 billion is spent annually in the U.S. for pain management, making it a significant part of the American health care system. In response, IGC has developed a series of drugs for pain and other disorders, including IGC-501 for neuropathic pain, IGC-502 for the treatment of seizures, and IGC-504 and IGC-506 for eating disorders and cachexia.

The company recently filed for issuance of a provisional patent for IGC-506, a combination of cannabis-based extracts and other compounds. It should be noted that a provisional patent does not assure the issuance of a patent in the future.

Mukunda explained that IGC is starting a review of international medical sites as the company seeks preclinical and clinical trials of its patent portfolio. He described the marketplace that IGC is entering as large, indicating that trials, patents and seeking approval from the U.S. Food & Drug Administration is seen as cost-effective.

For more information, visit the company’s website at www.IGCinc.us

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

India Globalization Capital, Inc. (NYSE: IGC) Pioneering New Phytocannabinoid Products

March 21, 2017

Although legal in 28 states for medicinal use, cannabis is still considered a dangerous substance in much of the country. However, many experts now believe that cannabis is a safe alternative to pharmaceuticals for relieving symptoms related to multiple illnesses. Scientific research shows that phytocannabinoids, cannabinoids that occur naturally in the cannabis plant, are effective at relieving convulsions, seizures, anxiety, nausea, and inflammation. From fighting glaucoma to controlling epileptic seizures and easing pain, scientific research has repeatedly shown the efficacy of medicinal marijuana.

Due to government misclassification of cannabis as a Schedule 1 drug, there has been only marginal progress in the utilization of phytocannabinoids, which hold such promise in disease treatment and pain mitigation. Although many pharmaceutical companies still avoid association with cannabinoids, attitudes are changing, and the medicinal benefits of marijuana are being recognized for their worth.

With changes in the acceptance of medicinal marijuana, some pharmaceutical companies are finally beginning to unpack the myriad of potential benefits phytocannabinoids hold. India Globalization Capital, Inc. (NYSE MKT: IGC) is pioneering such efforts. A multi-faceted company with global experience, India Globalization has a primary focus on developing novel cannabis-based therapies for the treatment of debilitating or life threatening conditions. The company’s current pipeline of patented drugs is focused on large market maladies, including therapeutics for neuropathic pain, human and animal seizures, refractory epilepsy, and eating disorders. Several of the company’s products are scheduled for pre-clinical trials this year.

A transformation is now underway in the medical use of cannabinoids for disease treatment, and India Globalization “believe(s) that the legalization of the cannabis industry will create an explosion in demand for cannabinoid-based pharmaceutical therapies, technology, facilities, and financial services.” With a patent portfolio of cannabinoid-based therapies, the company is well positioned for the quickly arriving time when medical cannabis gains widespread acceptance.

For more information, visit the company’s website at www.IGCinc.us

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

India Globalization Capital, Inc. (NYSE: IGC) is “One to Watch”

March 14, 2017

India Globalization Capital, Inc. (NYSE MKT: IGC) is a first mover in developing a portfolio of products using cannabis-based “combination therapies” for the treatment of pain and other conditions.

The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC’s patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.

The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson’s, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.

IGC’s strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. “The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner,” stated Ram Mukunda, CEO.

IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.

Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.

Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers’ Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York’s Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings.

For more information, visit the company’s website at www.IGCinc.us

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

India Globalization Capital, Inc. (IGC) Announces Profitable Third Quarter

February 14, 2013

India Globalization Capital has announced financial results for the third quarter ending Dec. 31, 2012.

“We are pleased to report profitability this quarter due to our considerable efforts to realign and focus our equipment, processes and people on the iron ore mining business, cut costs from unprofitable construction contracts and renegotiate or extinguish expense liabilities and debt,” said Ram Mukunda, CEO of India Globalization Capital. “Our revenues for the quarter rose dramatically to nearly $4 million, and we achieved earnings of $0.01 per share.”

The company’s total revenue was $3,933,906 for the three months ending Dec. 31; this is compared with $986,799 for the corresponding time period of 2011. This revenue increase resulted from a rise in trading activity as the company gears up for production in its mines. One revenue component of $802,746 was the result of closing out a construction contract that TBL, the company’s Indian subsidiary, was engaged in. In the next fiscal year beginning in April, TBL projects that revenue and margins will rise as iron ore prices are expected to trend up from increased infrastructure activity in China, India, the U.S., and other locations across the globe. It is the company’s current expectation to begin purchasing low-grade iron ore after the Chinese New Year and winter and to begin transporting it to plants for further beneficiation and sale to customers. IGC has four mines in Inner Mongolia and three beneficiation plants with more than $500 million in estimated reserves measured at $125 per ton.

During the three months that ended Dec. 31, IGC reported a GAAP net income of $310,892 and a GAAP EPS of $0.01 per share, as contrasted with a consolidated net loss of $1,901,375 and a GAAP EPS loss of $0.09 for the same three-month period of 2011. The substantial earnings shift is due to four factors: a significant cut in SG&A as the company aligns its resources for mining and trading; redeployment of construction equipment for mining; a marked decrease in high interest loans and liability; and a rise in iron ore trading revenue as well as revenue associated with the closure of a construction contract. As IGC beneficiates iron ore by converting low-grade iron ore to high-grade iron ore – in an environment where iron prices are trending higher – the arbitrage between low- and high-grade iron ore will increase and drive the company’s margins and earnings higher. IGC has put a great deal of energy into aligning its resources and integrating its mining business, and the company predicts that, based on current iron ore pricing trends, its next fiscal year will be profitable.

IGC’s selling, general, and administrative expenses for the period ending Dec. 31 were $153,789, as compared with $968,890 for the same period in 2011. The company has significantly cut employees and overheads and eliminated recurring contracts associated with construction activity.

IGC’s cash and cash equivalents, along with restricted cash, was around $2.1 million for the period ending Dec. 31. The company’s stockholders’ equity was around $15.6 million as of Dec. 31, as compared with around $15.8 million for the period ending March 31, 2012.

The company’s total reported assets were around $21.4 million as of Dec. 31, compared with around $25.3 million as of March 30, 2012.

“We are now filling orders from our Chinese customers through our trading operations,” said Mukunda. “We expect to increase this activity as we expand our suppliers beyond India and China. In the future, the lower margin trading business is expected to transition to higher margins as we supply high-grade iron ore from our beneficiation plants. As reported in Bloomberg, in September 2012 China approved $158 billion for infrastructure as part of a stimulus plan that is expected to boost the demand for commodities. Iron ore prices have started to recover from their lows of $86 per ton in September 2012 to around $125 per ton. We have about $500 million of iron ore deposits, four mine sites, and three beneficiation plants. Our short term strategy is three-pronged: 1) Start supplying high grade iron ore from our beneficiation plants; 2) Expand the supply chain for raw materials beyond India and China; and 3) Actively look at consolidating more mines in the Inner Mongolia region that can be accretive to the company.”

For more information, visit www.indiaglobalcap.com

Let us hear your thoughts below:

India Globalization Capital, Inc. (AMEX: IGC)

November 3, 2008

India Globalization Capital, Inc. (AMEX: IGC) is a company that was formed to acquire operating businesses located in India through merger, capital stock exchange, asset acquisition or other similar business combination. India Globalization Capital (IGC) has three main competencies which are: Highway and Heavy Construction, Mining and Quarrying, and Civil Construction and Engineering of high-temperature plants. IGC is a step ahead of their competition because they are the only Indian infrastructure company listed and trading in the United States. For further information, visit the company

RedChip Featured Company: India Globalization Capital, Inc. (IGC)

September 23, 2008

India Globalization Capital, Inc. (IGC) is a construction and engineering company based out of Bethesda, Maryland. IGC has controlling interest in two India-based businesses, Sricon Infrastructure Private Limited and Techni Bharathi Limited, which form its company infrastructure. Interestingly, IGC is the only company listed and traded in the US with an India-only infrastructure.

IGC was created to acquire operating businesses in India through mergers, capital stock exchanges, and asset acquisitions. The company focuses on three areas: civil construction and engineering of high-temperature cement and steel plants, mining and quarrying, and the construction of highways and other heavy construction.

IGC retains 63% of the equity of Sricon Infrastructure Private Limited, an infrastructure development company based in Nagpur, Maharashtra, India. At this time, Sricon operates 5 quarries from which it obtains construction aggregate. Sricon has participated in civil engineering construction projects since 1974 and now has the experience and qualifications to bid on contracts of up to $116 million.

IGC holds 77% of the equity of Techni Bharathi Limited, which is based out of Kerali, India. Techni is an engineering and construction company focused on developing the national infrastructure in India through the construction of roads, tunnels, canals, bridges, dams, airport taxiways, and hydro-power generation. Techri primarily works in the Indian states of Andhra Pradesh, Tamil Nadu, Karnataka, and Assam.

As India continues to be a major resource for out-sourcing services for U.S. companies, IGC will be there to support the construction of the country.

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

India Globalization (IGC) Reports 100% Increase in FY2008 Revenues

July 25, 2008

India Globalization Capital, Inc. (IGC:AMEX) is a US-based company developing infrastructure in India through its majority-owned subsidiaries, Sricon Infrastructure Private Ltd. and Techni Bharathi Ltd. On March 7, 2008 the company acquired 63% of Sricon Infrastructure and 77% of Techni Bharathi. The company, through its subsidiaries, has three core businesses: 1) highway and other heavy construction, 2) mining and quarrying, and 3) civil construction and engineering of high-temperature plants.

Recently, India Globalization announced a good set of results for the fiscal year ending March 31, 2008. The two subsidiaries combined reported revenues of $32.9 million and earnings of $4.4 million. The company’s CEO Ram Makunda said, “On a pro forma basis, our combined subsidiaries increased revenue by over 100% year-over-year with expanding margins.”

India, of course, is one of the BRIC countries with a booming economy and a huge population. It is well known that India is lagging behind China in building their infrastructure, and that India is sorely in need of infrastructure throughout the country. Since India Globalization is an infrastructure company in a country with tremendous demand for infrastructure, the demand for the company’s services is expected to grow nicely.

India Globalization’s order book does seem to be filling up. CEO Ram Makunda stated, “Based on our current order book, we expect record revenues and earnings and reaffirm our guidance for the fiscal year ending March 31, 2009 of revenue between $110 million to $125 million and earnings between $7 million to $9 million, before any one-time or non-cash charges.”

Let us hear your thoughts below:

Archives

Select A Month
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Search

    Categories

    Select A Category
  • 21st Century Holding Company TCHC (1)
  • 5BARz International Inc. BARZ (12)
  • 5G Wireless Communications Inc. FGWC (8)
  • 92 Resources Corp. RGDCF (12)
  • A.P. Pharma Inc. APPA (3)
  • Abazias Inc. ABZA (2)
  • ABcann Global Corp. ABCCF (18)
  • ABV Gold ABVG (11)
  • ACME Sports & Entertainment Inc. ASEN (2)
  • Adaptive Medias Inc. ADTM (6)
  • Advanced ID Corp. AIDO (5)
  • Advanced Medical Isotope Corp. ADMD (10)
  • Advanced Resources Group Ltd. AVRG (3)
  • Advanced Viral Research Corp. ADVR (9)
  • Advanced Visual Systems Inc. AVSC (10)
  • Advanced Voice Recognition Systems Inc. AVOI (11)
  • Advanced Wound Technologies Inc. AWTM (4)
  • Advaxis Inc. ADXS (2)
  • Agora Holdings Inc. AGHI (33)
  • Ahead of the Bulls (1)
  • AISystems, Inc. ASYI (11)
  • Aladdin Trading & Company ADTD (29)
  • Algae Dynamics Corp. ADYNF (31)
  • All American Gold Corp AAGC (13)
  • All Asia Licensing Inc. AASI (1)
  • ALL Fuels & Energy Company AFSE (49)
  • All Grade Mining Inc. HYII (3)
  • All Penny Stocks (3)
  • Allarae Healthcare Inc. ALHI (5)
  • Alliance Creative Group ACGX) (15)
  • Alliance Recovery Corp. ARVY (34)
  • Alltemp, Inc. LTMP (1)
  • AlphaTrade.com APTD (2)
  • Alpine TLI Group Inc. APGR (7)
  • ALR Technologies Inc. ALRT (9)
  • Alternative Construction Technologies Inc. ACCY (10)
  • Alternative Energy Development Corp. ADEC (1)
  • Alternative Fuel Technology Inc. AFTC (1)
  • Alternet Systems Inc. ALYI (47)
  • AM Oil Resources & Technology Inc. AMOR (8)
  • Amarin Corp. AMRN (2)
  • Amaru Inc. AMRU (2)
  • Amerex Group, Inc AEXG (16)
  • American Capital Partners Inc. APRJ (1)
  • American Fiber Green Products Inc. AFBG (1)
  • American Oriental Bioengineering Inc. AOB (3)
  • American Racing Capital Inc. AMRA (2)
  • American Software (2)
  • Amgen Inc. AMGN (2)
  • AmMex Gold Mining Corp. AMXG (2)
  • Ampex Corp AMPX (1)
  • Andover Medical Inc. ADOV (2)
  • Angstrom Microsystems Inc. AGMS (46)
  • Apolo Gold and Energy Inc. APLL (1)
  • Apple Inc. AAPL (13)
  • AppSwarm, Inc. SWRM (22)
  • Aquasil International Inc. AQUS (3)
  • Armco Metals Holdings Inc. AMCO (36)
  • AspenBio Pharma APPY (1)
  • Assured Pharmacy Inc. APHY (1)
  • Asta Funding Inc. ASFI (2)
  • Atlantic Energy Solutions Inc. AESO (1)
  • ATSI Communications Inc. ATSX (1)
  • Augme Technologies Inc. AUGT (70)
  • Auric Mining Corp. AUMY (3)
  • Automated Vending Technologies Inc. AVTC (3)
  • Automotive Company GNAU (11)
  • AV1 Group, Inc. AVOP (3)
  • Avalon Oil and Gas Inc. AOGN (16)
  • Avant Diagnostics Inc. AVDX (29)
  • Avatar Systems Inc. AVSY (3)
  • Axiom Management Inc. AXMA (3)
  • Axis Technologies Inc. AXTG (2)
  • B2Digital Inc. BTOD (18)
  • Balatia Airlines BLTA (2)
  • Bald Eagle Energy Inc. BEEI (18)
  • Banjo & Matilda Inc. BANJ (8)
  • Barchart.com (4)
  • Beacon Enterprise Solutions Group BEAC (47)
  • Beacon Equity Research (552)
  • Beijing Med-Pharm Corp. BGJP (2)
  • Bergamo Acquisition Corp. BGMO (15)
  • Big Tree Group Inc. BIGG (36)
  • Bio-Clean International Inc. BCLE (1)
  • Bio-Matrix Scientific Group Inc. BMSN (1)
  • BioCentric Energy Holdings Inc. BEHL (1)
  • Biomagnetics Diagnostics Corp. BMGP (3)
  • bioMETRX Inc. BMRX (1)
  • Bionic Products Corp. BNPD (4)
  • Biophan Technologies Inc. BIPH (1)
  • BioSolar Inc. BSRC (22)
  • Biotech Holdings Ltd. BIOHF (3)
  • BizRocket.com Inc. BZRT (9)
  • Black Diamond Brands Corp. BDMHF (1)
  • Blue Diamond Ventures Inc. BLDV (1)
  • Blue Moon Zinc Corp. BMOOF (7)
  • Blue Water Global Group Inc. BLUU (7)
  • Blugrass Energy Inc. BLUG (4)
  • Bollente Companies, Inc. BOLC (7)
  • BoonMarket.com (1)
  • Boreal Water Collection Inc. BRWC (23)
  • Boston Therapeutics Inc. BTHE (20)
  • Bridgetech Holdings International Inc. BGTH (1)
  • Brighton Oil & Gas Inc. BROG (8)
  • Britannia Mining Inc. BMIN (14)
  • Brite Strike Tactical Illumination Products, Inc. BSTI (41)
  • Brookside Technology Holdings Corp BKSD (2)
  • Bullzi Security Inc. BLLZ (3)
  • BWI Holdings Inc. BWIH (165)
  • Cache Elite Inc. ILUS (9)
  • Cal-Bay International Inc. CBYI (6)
  • Callisto Pharmaceuticals, Inc. (1)
  • Calpian Inc. CLPI (27)
  • CAMAC Energy Inc. CAK (2)
  • Canam Energy Inc. CNGJ (10)
  • CanAm Uranium Corp. CAUI (58)
  • Cannabics Pharmaceuticals Inc. CNBX (14)
  • Capital City Energy Group Inc. CETG (18)
  • Car Monkeys Group CKMY (15)
  • Carbon Sciences Inc. CABN (21)
  • CardioVascular BioTherapeutics Inc. CVBT (5)
  • Cardium Therapeutics Inc. CXM (44)
  • Cascade Technologies Inc. CSDT (2)
  • Cascadia Investment Inc. CDIN (4)
  • Casey Corp. CCPR (1)
  • Cashcow Magazine (4)
  • Cavico Corp. CVIC (3)
  • CD International Enterprises, Inc. CDII (48)
  • CDC Corp. CHINA (4)
  • CelebDirect Inc. CELI (3)
  • Cellceutix Corp. CTIX (18)
  • CellCyte Genetics Corp. CCYG (3)
  • Century Group, Inc. CEYG (1)
  • CEOcast (184)
  • CepTor Corp. CEPO (1)
  • Cereplast Inc. CERP (9)
  • Chancery Resources Inc. CCRY (3)
  • Changing Times Vitamins Inc. SGTB (12)
  • CHDT Corp. CHDO (5)
  • Cherubim Interests Inc. CHIT (36)
  • China 3C Group CHCG (13)
  • China America Holdings Inc. CAAH (8)
  • China Direct Inc. CDS (4)
  • China Education Alliance Inc. CEUA (4)
  • China Energy Recovery Inc. CGYV (12)
  • China Growth Development Inc. CGDI (2)
  • China Health Management Corp CNHC (7)
  • China Health Resource Inc. CHRI (14)
  • China INSOnline Corp. CHIO (1)
  • China Jiangsu Golden Horse Steel Ball Inc. CJGH (3)
  • China Logistics Group Inc. CHLO (11)
  • China Media Group Corp. CHMD (2)
  • China Medicine Corporation CHME (5)
  • China Nuvo Solar Energy Inc. CNUV (3)
  • China Organic Agriculture Inc. CNOA (11)
  • China Petroleum and Chemical Corp. SNP (2)
  • China Voice Holding Corp. CHVC (47)
  • China Wind Systems Inc. CWSI (6)
  • China Wireless Communications Inc. CWLC (4)
  • China Yongxin Pharmaceuticals Inc. CYXN (5)
  • China YouTV Corp. CYTV (1)
  • ChinaTel Group Inc. CHTL (1)
  • Chineseinvestors.com, Inc. CIIX (74)
  • ChromaDex Corp. CDXC (3)
  • City Capital Corp. CTCC (2)
  • Cityside Tickets CIST (21)
  • CleanTech BioFuels Inc. CLTH (10)
  • Cleantech Transit Inc. CLNO (3)
  • Clearly Canadian Beverage Corp. CCBEF (13)
  • Cleartronic Inc. CLRI (52)
  • Clenergen Corp. CRGE (37)
  • CMG Holdings Inc. CMGO (2)
  • Coastal Integrated Services Inc. COLV (13)
  • Coil Tubing Technology Inc. CTBG (1)
  • Colorado Goldfields Inc. CGFI (5)
  • Colt Resources Inc. COLTF (13)
  • Columbia River Resources Inc. CRVR (1)
  • CoMedia Corp. CMTN (1)
  • CommercePlanet Inc. CPNE (4)
  • Compress Technologies Inc. CTLG (17)
  • Conforce International Inc. CFRI (2)
  • Connect-A-Jet.com CAJT (9)
  • Cono Italiano Inc. CNOZ (12)
  • Consorteum Holdings, Inc. CSRH (160)
  • ContentChecked Holdings Inc. CNCK (60)
  • Continental Fuels Inc. CFUL (2)
  • Converde Energy USA Inc. XFUL (12)
  • Convergence Technology Group Inc. CNVC (7)
  • Copper King Mining Corp. CPRK (2)
  • Cord Blood America Inc. CBAI (102)
  • Crdentia Corp CRDT (12)
  • Creative Vistas Inc. CVAS (2)
  • Crystal International Travel Group Inc. CINT (4)
  • Cubic Energy Inc. QBC (2)
  • Cybermesh International Corp. CYTL (1)
  • Cyclone Power Technologies Inc. CYPW (9)
  • CYIOS Corp. CYIO (1)
  • Daily Views (13)
  • Dakshidin Corp. DKSC (5)
  • Data Call Technologies Inc. DCLT (25)
  • Daulton Capital Corp. DUCP (26)
  • Davi Skin Inc. DAVN (1)
  • Debt Resolve Inc. DRV (2)
  • Debut Broadcasting Corporation Inc. DBTB (1)
  • Deep Blue Marine Inc. DPBM (6)
  • Deep Down Inc. DPDW (15)
  • Deer Valley Corp. DVLY (2)
  • Defense Solutions Inc. DFSH (3)
  • Delta Mining and Exploration Corp. DMXC (1)
  • Dermisonics Inc. DMSI (1)
  • Destination Television Inc. DSTV (17)
  • Dhanoa Minerals Ltd. DHNA (4)
  • DigitalPost Interactive Inc. DGLP (8)
  • Document Capture Technologies Inc. DCMT (3)
  • DoMark International Inc. DOMK (29)
  • Dominovas Energy Corp. DNRG (73)
  • Dragon Capital Group Corp. DRGV (11)
  • Dragon International Group Corp. DRGG (2)
  • Duma Energy Corp. DUMA (20)
  • Duska Therapeutics Inc. DSKA (1)
  • Dutton Associates (88)
  • DXP Enterprises Inc. DXPE (4)
  • Dynamic Media Holdings Inc. DYMH (6)
  • Dynamic Response Group Inc. DRGP (6)
  • Dynasty Limousine Inc. DNYS (19)
  • Earth Dragon Resources Inc. EARH (10)
  • Eastbridge Investment Group Corp. EBIG (1)
  • Ebenefits Direct, Inc. EBFD (21)
  • eCareer Holdings Inc. ECHI (9)
  • Echo Therapeutics Inc. ECTE (5)
  • EcoloCap Solutions Inc. ECOS (2)
  • Ecologic Transportation Inc. EGCT (11)
  • Ecosciences Inc. ECEZ (1)
  • Ecotality, Inc. ECTY (67)
  • eCrypt Technologies Inc. ECRY (79)
  • EdgeTech International Inc. EGIL (6)
  • eDoorways Corp. EDWY (183)
  • EFoodSafety.com Inc. EFSF (4)
  • EFuel EFN Corp. EFUL (1)
  • EGPI Firecreek Inc. EFIR (1)
  • Elephant Talk Communications Corp. ETAK (8)
  • Elephant Talk Communications Inc. ETAK (2)
  • Elleipsis Global Travel Solutions Inc. EGTS (3)
  • Elray Resources Inc. ELRA (11)
  • Elron Electronic Industries Ltd. ELRN (1)
  • Emerging Media Holdings Inc. EMDH (22)
  • Empire Energy Corporation International EEGC (3)
  • Endeavor Explorations Inc. EAVR (7)
  • Endeavour Silver Corp. EXK (3)
  • Endevco Inc. EDVC (2)
  • Energtek Inc. EGTK (61)
  • Enherent Corp. ENHT (2)
  • EnterConnect Inc. ECNI (5)
  • Enterprise Oilfield Group Inc. E.TO (13)
  • EnXnet Inc. EXNT (1)
  • Epazz, Inc. EPAZ (28)
  • Equity Stock Analysis (1)
  • ER Urgent Care Holdings Inc. ERUC (6)
  • ERF Wireless Inc. ERFB (15)
  • Essential Innovations Technology Corp. ESIV (2)
  • Etelcharge.com Inc. ETLC (3)
  • Ethema Health Corporation GRST (7)
  • Euoko Group Inc. EUOK (2)
  • EV Innovations Inc. EVII (189)
  • EV Transportation Inc. EVTP (7)
  • EVIO, Inc. EVIO (9)
  • Exchange Media Corp. EXMD (9)
  • Exeter Resource Corp. XRA (2)
  • eXp World Holdings, Inc. EXPI (81)
  • Expert Group Inc. EXPT (5)
  • ExpressIR Inc. (1)
  • Extreme Motorsports of California, Inc. EMOC (26)
  • ezBanc-A Stocklender's Journal (6)
  • Falcon Crest Energy FCEN (75)
  • Falcon Ridge Development Inc. FCNR (2)
  • Famous Uncle Als Hot Dogs & Grille Inc FDOG (10)
  • Fastfunds Financial Corp. FFFC (17)
  • Financial Media Group, Inc. FNGP (26)
  • Financial Services Exchange FSE (1)
  • First Cobalt Corp. FTSSF (5)
  • First Titan Corp. FTTN (45)
  • FlexWeek Inc. FXWK (11)
  • FluoroPharma Medical Inc. FPMI (46)
  • Foldera, Inc. FDRA (11)
  • Force Energy Corp. FORC (5)
  • FormCap Corp. FRMC (29)
  • Fortune Market Media Inc. FTMM (5)
  • Franklin Mining Inc. FMNJ (1)
  • Freedom Leaf Inc. FRLF (12)
  • Fresh Harvest Products Inc. FRHV (7)
  • Fresh Promise Foods Inc. FPFI (12)
  • Freshstart Properties Inc. FSPP (1)
  • FrogAds Inc. FROG (6)
  • Frozen Food Gift Group Inc. FROZ (5)
  • Fund.com, Inc. FNDM (56)
  • Fushi Copperweld Inc. FSIN (2)
  • GainClients Inc. GCLT (9)
  • Galenfeha Inc. GLFH (28)
  • Gastar Exploration Ltd. GST (2)
  • Gemini Explorations Inc. GXPI (12)
  • Gen2media Corp. GTWO (2)
  • General Environmental Management Inc. GEVI (56)
  • General Metals Inc. GNMT (1)
  • General Steel Holdings Inc. GSI (3)
  • GeoBio Energy Inc. GBOE (1)
  • GeoEye Inc. GEOY (4)
  • GeoPharma Inc GORX (1)
  • Giggles N’ Hugs Inc. GIGL (90)
  • Global Alumina Corp. GLA.U (1)
  • Global General Technologies Inc. GLGT (1)
  • Global Payout Inc. GOHE (64)
  • Global Realty Development Corp. GRLY (10)
  • Global Resource Corporation GBRC (48)
  • Global Roaming Distribution Inc. GRDB (34)
  • GlobalWise Investments Inc. GWIV (129)
  • GNCC Capital Inc. GNCP (24)
  • Golden West Brewing Company Inc. GWBC (3)
  • GoldSpring Inc. GSPG (4)
  • Google, Inc. GOOG (8)
  • GotStocks.net (1)
  • Grandview Gold Inc. GVGDF (2)
  • Gray Publishing & Media, Inc. GPMIJ (15)
  • Graystone Park Enterprises Inc. GPKE (7)
  • Great Plains Holdings Inc. GTPH (28)
  • Green Earth Technologies GETG (1)
  • Green Star Alternative Energy Inc. GSAE (2)
  • Green Star Products Inc. GSPI (2)
  • Green Technology Solutions Inc. (GTSO) (19)
  • Greenbelt Resources Corp. GRCO (1)
  • Greenchek Technology Inc. GCHK (18)
  • Greenkraft, Inc. GKIT (13)
  • Greenstone Holdings Inc. GSHN (2)
  • GREM USA GRMU (2)
  • Grey Cloak Tech, Inc. GRCK (14)
  • GRILLiT Inc. GRLT (8)
  • Growblox Sciences Inc. GBLX (24)
  • GT Legend Automotive Holdings Inc. GTLA (2)
  • GTX Corp GTXO (49)
  • Gulf Western Petroleum Corp. GWPC (3)
  • GWS Technologies Inc. GWSC (4)
  • Halcyon Jets Holdings Inc. HJHO (15)
  • Halitron Inc. HAON (11)
  • Hanover Financial Services (17)
  • Harbin Electric Inc. HRBN (2)
  • Harvey Electronics Inc. HRVE (1)
  • Hasco Medical Inc. HASC (7)
  • Hathway Corp. HWYI (1)
  • HeadsUp Entertainment International Inc. HDUP (3)
  • Healthnostics Inc. HNSO (1)
  • HealthSonix Inc. HSXI (1)
  • HealthSport Inc. HSPO (14)
  • Heartland Inc. HTLG (1)
  • Heartland Oil and Gas Corp. HTOG (7)
  • Hemis Corporation HMSO (19)
  • Hemisphere Gold Inc. HPGI (1)
  • Hemp Inc. HEMP (25)
  • Hendrx Corp. HDRX (1)
  • Hi-Shear Technology Corp. HSR (3)
  • HighCom Global Security Inc. HCGS (17)
  • HII Technologies Inc. HIIT (8)
  • Holloman Energy Corp. HENC (2)
  • Holmes Osborne (6)
  • Hologic Inc. HOLX (4)
  • Home Shopping Latino Inc. HSPG (8)
  • Hong Kong Highpower Technology Inc. HPJ (2)
  • HotOTC (61)
  • HotStockChat (3)
  • HotStockMarket (HSM) (3)
  • HST Global Inc. HSTC (11)
  • Hunt Gold Corp. HGLC (32)
  • HWI Global Inc. HWIC (3)
  • Hydrogen Corp. HYDG (1)
  • i-Level Media Group Inc. ILVL (3)
  • i2 Telecom International Inc. ITUI (7)
  • iB3 Networks Inc. IBNW (1)
  • IceWEB Inc. IWEB (5)
  • ICP Solar Technologies Inc. ICPR (3)
  • IDGLOBAL Corp. IDGJ (2)
  • IDO Security Inc. IDOI (22)
  • IFAN Financial Inc. IFAN (34)
  • iGambit, Inc. IGMB (5)
  • Imaging3 Inc. IMGG (2)
  • ImaRx Therapeutics Inc. IMRX (2)
  • Immune Therapeutics Inc. IMUN (11)
  • Impact E-Solutions Corp. IESO (1)
  • Imperial Petroleum Inc. IPMN (10)
  • Inca Designs Inc. IDGI.PK (4)
  • Independent Film Development Corp. IFLM (1)
  • Index Oil and Gas Inc. IXOG.OB (5)
  • India Globalization Capital, Inc. IGC (21)
  • Industrial Biotechnology Corp. IBOT (1)
  • Infinite Group Inc. IMCI (48)
  • Inform Worldwide Holdings, Inc. IWWI (27)
  • InMed Pharmaceuticals, Inc. IMLFF (35)
  • Intec LTD ICLJY (1)
  • IntegraMed America Inc INMD (1)
  • Intelecom Inc. IECM (3)
  • Intelimax Media Inc. IXMD (31)
  • Intelligent Highway Solutions Inc. IHSI (6)
  • Intercept Energy Services Inc. IESCF (7)
  • Interleukin Genetics Inc. ILI (1)
  • International Barrier Technology Inc IBTGF (1)
  • International Consolidated Companies Inc. INCC (2)
  • International Stem Cell Corp. ISCO (226)
  • Inventergy Global Inc. INVT (15)
  • Investor Village (9)
  • Investors Business Daily (4)
  • InvestorsProfs (1)
  • InvestSource (11)
  • IPOs (8)
  • IR Biosciences Holdings Inc IRBS (3)
  • Isonics Corp. ISON (1)
  • ItsAboutFinance (2)
  • JC Data Solutions Inc. JCDS (4)
  • Joytoto USA Inc. JYTO (14)
  • JZZ Technologies Inc. JZZI (3)
  • KAL Energy Inc. KALG (3)
  • Kallo Inc. KALO (43)
  • Kandi Technologies Corp. KNDI (3)
  • KCM Holding Corp. KCMH (3)
  • Kingslake Energy Inc. KGLJ (2)
  • Klondex Mines Ltd. KLNDF (1)
  • Knobias KNBS (5)
  • Kootenay Zinc Corp. KTNNF (12)
  • Kraig Biocraft Laboratories Inc. KBLB (88)
  • L&L International Holdings Inc. LLFH (2)
  • Laguna Blends Inc. LAGBF (53)
  • Lantis Laser Inc. LLSR (5)
  • Last Mile Logistics Group LMLG (4)
  • Latitude 360 Inc. LATX (21)
  • LD Holdings Inc. LDHL (14)
  • Legacy Holdings Inc. LGYH (1)
  • Legacy Ventures International Inc. LGYV (24)
  • Legend Media Inc. LEGE (4)
  • Lexaria Bioscience Corp. LXRP (36)
  • Lifespan Inc. LSPN (1)
  • Lime Energy Corp. LIME (3)
  • Lingo Media Corp. LMDCF (18)
  • Linkwell Corporation LWLL (4)
  • Liquor Group Wholesale Inc. LIQR (22)
  • Loans4Less.com Inc. LFLS (47)
  • LOGIC Devices Inc. LOGC (1)
  • Logility Inc. LGTY (1)
  • LoJack Corp LOJN (3)
  • Longhai Steel Inc. LGHS (10)
  • LottoGopher Holdings Inc. LTTGF (18)
  • Lotus Pharmaceuticals Inc. LTUS (1)
  • Low Carbon Technologies (LWCTF) (3)
  • Lucas Energy, Inc. LEI (17)
  • Mabwe Minerals Inc. MBMI (56)
  • Macquarie Infrastructure Company MIC (5)
  • Maine and Maritime Corp. MMA (1)
  • Majic Wheels Corp. MJWL (6)
  • Makeup Inc. MAKU (2)
  • Mammoth Energy Group Inc. MMTE (5)
  • Mantra Venture Group Ltd. MVTG (10)
  • Marijuana Company of America, Inc. MCOA (11)
  • Mariner’s Choice International Inc. MCII (2)
  • Martin Nutraceuticals MNIU (11)
  • Material Technologies Inc. MTCH (44)
  • Max Media Group Inc. MXMI (9)
  • Max Sound Corp. MAXD (30)
  • MC Endeavors Inc. MSMY (2)
  • MedeFile International Inc. MDFI (46)
  • MediaG3 Inc. MDGC (1)
  • Medical Cannabis Payment Solutions (REFG) (1)
  • Medical Cannabis Payment Solutions REFG (2)
  • Medical Innovation Holdings, Inc. MIHI (9)
  • Medical Transcription Billing Corp. MTBC (13)
  • Medina International Holdings Inc. MIHI (3)
  • Medisafe 1 Technologies Corp. MFTH (3)
  • Medivisor Inc. MVSR (1)
  • Mega Media Group, Inc. MMDA (30)
  • MegaWest Energy Corporation MGWSF (2)
  • Memry Corp. MRY (2)
  • Metro One Development Inc. MODI (2)
  • Mexico Energy Corp. MXC (1)
  • MGX Minerals, Inc. MGXMF (12)
  • Micro Identification Technologies Inc. MMTC (44)
  • MicrocapMoney (2)
  • Microsoft Corporation MSFT (4)
  • Midway Gold Corp. MDW (1)
  • Military Resale Group MYRL (19)
  • Minco Silver Corp. MSV.TO (1)
  • Mindpix Corp. MNDP (1)
  • MIP Solutions Inc. MSOL (7)
  • MIT Holding MITD (36)
  • MitoPharm Corp. MTPH (1)
  • Mizati Luxury Alloy Wheels, Inc. MZTI (14)
  • Mobile Entertainment Inc. MBEI (1)
  • Mobile Lads Corp. MOBO (43)
  • Momentous Entertainment Group Inc. MMEG (19)
  • Monaker Group Inc. MKGI (48)
  • Money4Gold Holdings Inc. MFGD (3)
  • MortgageBrokers.com Holdings Inc. MBKR (2)
  • Mosquito Consolidated Gold Mines Limited MSQ.V (1)
  • Moxian Inc. MOXC (62)
  • mPhase Technologies Inc. XDSL (12)
  • MSE Enviro-Tech Corp. MEVT (4)
  • Muscle Flex Inc. MFLI (55)
  • MusclePharm Corp. MSLP (23)
  • Mvive Inc. MVIV (22)
  • My Automated Advisor (4)
  • MyECheck Inc. MYEC (99)
  • MyStaru.com Inc. MYST (1)
  • Nanogen Inc. NGEN (2)
  • Nanometrics Inc. NANO (1)
  • NanoSensors Inc. NNSR (1)
  • NanoTech Entertainment Inc. NTEK (30)
  • Napster, Inc. NAPS (5)
  • National Automation Services Inc. NASV (67)
  • National Coal Corp. NCOC (2)
  • National Waste Management Holdings Inc. NWMH (24)
  • Naturally Iowa Inc. NLIA (2)
  • NavStar Technologies Inc. NVSR (16)
  • nCoat Inc NCOA (8)
  • Neah Power Systems NPWZ (14)
  • Neohydro Technologies Corp. NHYT (4)
  • Neoprobe Corp. NEOP (6)
  • NeoStem Inc. NBS (6)
  • Net Element Inc. NETE (19)
  • NetSol Technologies Inc NTWK (64)
  • Neurobiological Technologies Inc. NTII (3)
  • NeuroMama Ltd. NERO (15)
  • Neutra Corp. NTRR (37)
  • New Asia Gold Corp. NWAG (1)
  • New Generation Biofuel Holdings Inc. GNB (3)
  • NewMarket China Inc. NMCH (7)
  • NewMarket Technology Inc. NMKT (7)
  • Newport Digital Technologies Inc. NPDT (61)
  • Nexia Holdings Inc. NXHD (51)
  • NexMed Inc. NEXM (8)
  • NeXplore Corp. NXPC (4)
  • Next One Interactive Inc. NXOI (7)
  • NextGen Bioscience Inc. NXGB (1)
  • NextPhase Wireless Inc. NPHS (1)
  • Nexus Enterprise Solutions Inc. NXES (30)
  • NF Energy Saving Corp. of America NFES (1)
  • Nhale Inc. NHLE (18)
  • Nilam Resources Inc. NILR (4)
  • Nitro Petroleum Inc. NTRO (5)
  • North Bay Resources Inc. NBRI (10)
  • NuTech Inc. NTCI (1)
  • Nutra Pharma Corp. NPHC (21)
  • NutraNomics Inc. NNRX (30)
  • NuVim Inc. NUVM (1)
  • NVIDIA Corp. NVDA (1)
  • NXGen Holdings Inc. NXGH (1)
  • Oakridge Global Energy Solutions Inc. OGES (63)
  • Obee's Franchise Systems Inc. OBFM (1)
  • OBJ Enterprises Inc. OBJE (27)
  • Odyne Corporation ODYC (15)
  • Omega Commercial Finance Corp. OCFN (2)
  • OmniaLuo Inc. OLUO (1)
  • Omnicity Corp. OMCY (26)
  • Omninet Media.Com, Inc. ONMC (5)
  • On The Go Healthcare Inc. MODI (13)
  • On the Move Systems Inc. OMVS (102)
  • Oncolin Therapeutics Inc. OCOL (1)
  • One Step Vending Corp. KOSK (2)
  • One World Holdings Inc. OWOO (61)
  • Ones to Watch (1,353)
  • Onstream Media Corp. ONSM (5)
  • Onteco Corp. ONTC (4)
  • Open Energy Corp. OEGY (4)
  • Optical Systems Inc. OPSY (2)
  • Oramed Pharmaceuticals Inc. ORMP (2)
  • Organic Alliance Inc. ORGC (2)
  • ORHub, Inc. ORHB (26)
  • OTCPicks.com (82)
  • OtcStockExchange (5)
  • OurPet's Company OPCO (78)
  • OxySure Systems Inc. OXYS (23)
  • P2 Solar Inc. PTOS (24)
  • Pacific Gold Corp. PCFG (3)
  • Pamplona Picks (1)
  • Pan Global Corp. PGLO (82)
  • PanGenex Corp. PGCX (3)
  • Paramount Gold and Silver Corp. PZG (3)
  • Patient Access Solutions Inc. PASO (7)
  • Patriot Energy Corp. dba TelTeck Solutions Inc PGYC.PK (11)
  • Patriot One Technologies, Inc. PTOTF (24)
  • Patriot Scientific Corp. PTSC (6)
  • Peace Arch Entertainment Group Inc. PAE (1)
  • Peoples Educational Holdings Inc. PEDH (2)
  • Perf Go Green Holdings Inc. PGOG (12)
  • Perfect Web Technologies, Inc PWBI (11)
  • Perfectenergy International Ltd. PFGY (1)
  • Performance Health Technologies Inc. PFMH (31)
  • Pet DRX Corp. VETS (1)
  • Petro Resources Corp. PRC (2)
  • PetroSun Inc. PSUD (41)
  • Petroteq Energy Inc. PQEFF (4)
  • Phantom Fiber Corp. PHFB (2)
  • Pilot Financial Communications (3)
  • Pipex Pharmaceuticals Inc. PP (2)
  • PITOOEY! Inc. PTOO (14)
  • Planet Nutrition Inc. PNHL (4)
  • Platina Energy Group Inc. PLTG (8)
  • PlayBOX Inc. PYBX (5)
  • Players Network PNTV (15)
  • Pluristem Therapeutics Inc. PSTI (10)
  • Positron Corp. POSC (3)
  • PotNetwork Holding, Inc. POTN (23)
  • Power of the Dream Ventures (1)
  • Power Play Development Corp. PWPY (17)
  • Powersafe Technology Corp. PWSF (1)
  • Premier Energy Corp. PNRC (1)
  • Pressure BioSciences Inc. PBIO (41)
  • PRG Group Inc. PRGJ (2)
  • PrimEdge Inc. PEDI (1)
  • Private Equity Securities (93)
  • Pro Motors Group Corp. PMGU (2)
  • Pro Travel Network Inc. PTVL (2)
  • ProBility Media Corp. PBYA (33)
  • ProGaming Platforms Corp. PPTF (22)
  • Proginet Corp. PRGF (3)
  • Prom Resources PRMO (9)
  • Propalms Inc. PRPM (3)
  • Provectus Pharmaceuticals Inc. PVCT (12)
  • Puget Technologies Inc. PUGE (23)
  • Pulmo BioTech Inc. PLMO (4)
  • Puramed Bioscience Inc. PMBS (3)
  • Pure Biofuels Corp. PBOF (4)
  • Pure H2O Inc. PURH (1)
  • Pure Hospitality Solutions Inc. PNOW (99)
  • Purio Inc. PURO (5)
  • Puritan Financial Group Inc. PTNG (1)
  • Purple Beverage Company Inc. PPBV (8)
  • QED Connect Inc. QEDC (4)
  • Qiao Xing Universal Telephone Inc. XING (2)
  • QPC Lasers Inc. QPCI (3)
  • Qualcomm Inc. QCOM (2)
  • QualityStocks for Women (16)
  • QualityStocks Partner StockGuru (3,878)
  • QualityStocks Stock Newsletter (551)
  • QualityStocks Stock Newsletters (18,172)
  • QualityStocks Video Charts (286)
  • QualityStocks.net Market Basics (6)
  • QualityStocksNewsBreaks (321)
  • Quantum Fuel Systems Technologies Worldwide Inc. QTWW (15)
  • Quantum International Corp. QUAN (3)
  • Quasar Aerospace Industries Inc. QASP (6)
  • QuoteMedia Inc. QMCI (120)
  • Rafarma Pharmaceuticals Inc. RAFA (31)
  • Rainbow Coral Corp. RBCC (33)
  • Rancher Energy Corp. RNCH (9)
  • Raptor Resources Holdings Inc. RRHI (50)
  • Raven Gold Corp. RVNG (3)
  • Red Lake Exploration Inc. RLKX (19)
  • RegalWorks Media Inc. RWMI (4)
  • Regenicin, Inc. RGIN (6)
  • Reliant Financial Services Inc. RFNS (1)
  • Renhuang Pharmaceuticals Inc. RHGP (3)
  • ReoStar Energy Corp. REOS (1)
  • Resort Savers Inc. (RSSV) (10)
  • Revett Minerals (1)
  • RJD Green Inc. RJDG (9)
  • Rock Energy Resources Inc. RCKE (4)
  • Rodman & Renshaw (432)
  • Ronn Motor Company Inc. RNNM (6)
  • Rox Resources Ltd. RXRS (3)
  • Royal Quantum Group, Inc. RYQG (10)
  • Royal Standard Minerals Inc. RYSMF (2)
  • Rudy Nutrition RUNU (27)
  • RXi Pharmaceuticals Corp. RXII (3)
  • Santa Fe Gold Corp. SFEG (5)
  • Santa Fe Holding Company SFHD (3)
  • Save The World Air Inc. ZERO (12)
  • Savoy Energy Corp. SNVP (26)
  • SavWatt USA, Inc. SAVW (5)
  • Seabridge Gold Inc. SA (1)
  • Seawright Holdings Inc. SWRI (1)
  • Sector 10 Inc. SECI (78)
  • SES Solar Inc. SESI (2)
  • Seven Arts Pictures plc SAPX (1)
  • Seven Arts Pictures PLC SAPXF (5)
  • Shazam Stocks (22)
  • ShotPak Inc. SHTP (35)
  • Shumate Industries SHMTE (1)
  • Sibling Group Holdings Inc. SIBE (55)
  • Sierra Gold Corp. SGCP (2)
  • Signature Devices Inc. SDVI (9)
  • Silver Dragon Resources Inc. SDRG (1)
  • Silver Falcon Mining Inc. SFMI (1)
  • SilverSun Technologies Inc. SSNT (30)
  • Simtrol Inc. SMRL (74)
  • Simulated Environment Concepts Inc. SMEV (130)
  • Singlepoint Inc. SING (113)
  • Sino Agro Food Inc. SIAF (1)
  • Sinobiomed Inc. SOBM (4)
  • Sinovac Biotech Ltd SVC (1)
  • Sipp Industries Inc. SIPC (2)
  • Skinny Nutritional Corp. SKNY (19)
  • Skinvisible, Inc. SKVI (10)
  • Sky Petroleum Inc. SKPI (1)
  • SkyPostal Networks Inc. SKPN (66)
  • Small Cap Sentinel (2)
  • Small Cap Sleeper (3)
  • Smallcap Bullets (2)
  • Smallcaps.us (22)
  • SmallCapVoice (428)
  • Smoky Market Foods Inc. SMKY (9)
  • SocialPicks (1)
  • Sofame Technologies Inc SDW.V (1)
  • Sohm Inc. SHMN (14)
  • Solanex Management Inc. SLNX (15)
  • Solar Energy Initiatives Inc. SNRY (14)
  • Solar Wind Energy Tower Inc. SWET (15)
  • Solarfun Power Holdings Co. Ltd. SOLF (2)
  • Soul and Vibe Interactive Inc. SOUL (14)
  • South Sea Energy Corp. SSGY (7)
  • Soyo Group Inc SOYO (2)
  • SpaceDev Inc. SPDV (5)
  • Sparta Commercial Services Inc. SRCO (31)
  • Speedemissions Inc. SPMI (14)
  • Spicy Pickle Inc SPKL (18)
  • SpongeTech Delivery Systems Inc. SPNG (14)
  • Sports Pouch Beverage Company Inc. SPBV (1)
  • Star Mountain Resources Inc. SMRS (37)
  • Start Scientific Inc. STSC (22)
  • Stealth Technologies, Inc. STTH (3)
  • Stock Market E-News (1)
  • Stock Promoters (4)
  • StockEgg (14)
  • Stocks to Watch (1,926)
  • StocksJournal (2)
  • StockUPTicks (165)
  • Stockwire (6)
  • Strategic American Oil Corp SGCA (32)
  • Stratos Renewables Corp. SRNW (89)
  • StreamTrack Inc. STTK (31)
  • Striker Oil & Gas Inc. SOIS (4)
  • Sun Motor International Inc. SNMO (1)
  • SUN Sports & Entertainment Inc. SSPE (3)
  • Sunshine Biopharma Inc. SBFM (6)
  • Superlattice Power Inc. SLAT (60)
  • SupportSave Solutions, Inc. SSVE (10)
  • Surefect Holdings Inc. SUFH (1)
  • Suspect Detection Systems Inc. SDSS (37)
  • Sweet Success Enterprises Inc. SWTS (35)
  • Swiss Hawk AG SWHKF (1)
  • Symposium Production Corp. SYPJ (1)
  • Tactical Air Defense Services, Inc. TADF (15)
  • Tao Minerals Ltd. TAOL (1)
  • TapImmune, Inc. TPIV (15)
  • Tapinator, Inc. TAPM (10)
  • Taplmmune Inc. TPIM (1)
  • Technology Applications International Inc. NUUU (25)
  • TechPrecision Corp. TPCS (4)
  • Tecton Corp. TTNC (3)
  • Teknik Digital Arts Inc. TKNK (10)
  • Telanetix Inc. TNXI (2)
  • Teletouch Communications Inc. TLLE (5)
  • Terax Energy Inc. TEXG (32)
  • Terme Bancorp TMEB (1)
  • Terra Nostra Resources Corp. TNRO (25)
  • The Amergence Group AMNG (8)
  • The Aristocrat Group Corp. ASCC (113)
  • The Bowser Report (68)
  • The Bull Report (32)
  • The Capital Report (5)
  • The DIRECTV Group Inc. DTV (1)
  • The Fight Zone Inc. TFZI (12)
  • The Green Organic Dutchman Holdings Ltd. TGOD (3)
  • The Guitammer Company Inc. GTMM (38)
  • The International Traders Expo (30)
  • The Mobile Star Corp. MBST (7)
  • The Motley Fool (3)
  • The Mundus Group Inc. MNDS (1)
  • The Penny Stock Blog (28)
  • The Principal Structure Fund, Inc. PSF (2)
  • The Tracking Corp. TRKG (1)
  • The UpTurn, Inc. UPTR (20)
  • The Wall Street Savant (24)
  • The Wide Angle (3)
  • Thresher Industries Inc. THRR (15)
  • Tidelands Oil and Gas Corp. TIDE (1)
  • Tiens Biotech Group USA Inc. TBV (1)
  • TMT Capital Corp. TMTP (1)
  • TNI BioTech Inc. TNIB (16)
  • Tombstone Exploration Corp. TMBXF (9)
  • TOMI Environmental Solutions Inc. TOMZ (4)
  • Tootie Pie Company, Inc. TOOT (11)
  • Torchlight Energy Resources, Inc. TRCH (2)
  • TradeShow Marketing Company Inc. TSHO (21)
  • TransWorldNews (4)
  • Tri-Star Holdings Inc. TSHL (31)
  • Trimax Corp. TMXN (31)
  • TripleCrownStocks (9)
  • True 2 Beauty Inc. TRTB (43)
  • TwinTrader (8)
  • TXP Corporation TXPO (1)
  • TZ Ltd. TZL.AX (1)
  • U.S. Mine Makers Inc. USMM (1)
  • uKarma Corporation UKMA (1)
  • Ultitek Ltd. UITK (21)
  • Unbridled Energy Corporation TSX-UNE (21)
  • Unico Inc. UNCO (3)
  • Universal Bioenergy Inc. UBRG (3)
  • Universal Detection Technology UNDT (41)
  • Universal Energy Corp. UVSE (19)
  • Universal Property Development and Acquisition UPDA (4)
  • Universal Tracking Solutions Inc. UTRK (13)
  • Universal Travel Group UTVG (14)
  • UpSNAP Inc. UPSN (1)
  • Uranium Energy Corp. UEC (64)
  • Uranium Hunter Corp. URHN (17)
  • Urex Energy Corp. URXE (1)
  • USA Recycling Industries Inc. USRI (21)
  • USA Superior Energy Inc. USSU (9)
  • Ustelematics Inc. UTLM (27)
  • Utah Uranium Corp. UTUC (2)
  • Utilicraft Aerospace Industries Inc. UITA (2)
  • ValueRich & iValueRich (9)
  • Vaporin Inc. VAPOD (2)
  • VentriPoint Diagnostics Ltd. VPTDF (26)
  • Vermillion Inc. VRML (3)
  • Vertical Branding Inc. VBDG (11)
  • VIASPACE, Inc. VSPC (185)
  • Victory Energy Corp. VYEY (29)
  • Vidshadow Inc. VSHD (1)
  • View Systems Inc. VSYM (16)
  • Viper Networks Inc. VPER (2)
  • Viral Genetics Inc. VRAL (3)
  • Viropro International Inc. VPRO (2)
  • VirTra Systems Inc. VTSI (22)
  • Viscount Systems Inc. VSYS (27)
  • visionGATEWAY Inc. VGWA (1)
  • VistaGen Therapeutics Inc. VSTA (104)
  • Visualant Inc. VSUL (5)
  • Vital Products Inc. VTLP (5)
  • Viyya Technologies Inc. VYON (2)
  • VizStar Inc VIZS (24)
  • Voiceserve Inc. VSRV (18)
  • Vortex Resources Corp. VTEX (7)
  • Vsurance Inc. VSUR (3)
  • Vyteris Inc. VYHN (1)
  • W2 Energy Inc. WWEN (13)
  • Wall Street News Alert (76)
  • WallStreetGrapevine (12)
  • WaterPure International Inc. WPUR (4)
  • Wave Systems Corp. WAVX (5)
  • Week in Review (2)
  • Well Power Inc. WPWR (77)
  • Wescorp Energy Inc. WSCE (18)
  • West Canyon Energy Corp. WCYO (1)
  • Western Standard Energy Corp. WSEG (7)
  • Who's Your Daddy Inc. WYDI (7)
  • WikiLoan Inc. WKLI (14)
  • Wind Energy America Inc. WNEA (3)
  • Wisdom Homes of America Inc. WOFA (15)
  • Wits Basin Precious Minerals Inc. WITM (2)
  • Woize International Ltd. WOIZ (1)
  • WordLogic Corp. WLGC (40)
  • Workstream Inc. WSTM (9)
  • WorldWater & Solar Technologies Corp. WWAT (10)
  • Worldwide Energy and Manufacturing WEMU (12)
  • Worldwide Manufacturing USA Inc. WWMU (6)
  • WRIT Media Group Inc. WRIT (36)
  • X-Change Corp. (XCHC) (2)
  • Xaar Plc XAARF (1)
  • Xenomics Inc. XNOM (1)
  • XsunX Inc. XSNX (17)
  • XZERES Corp. XPWR (2)
  • Younger America YNGR (13)
  • Zacks Investment Research (11)
  • ZAGG Inc. ZAGG (9)
  • Zaldiva Inc. ZLDV (3)
  • ZAP ZAAP (15)
  • ZBB Energy Corp ZBB (7)
  • Zenosense Inc. ZENO (53)
  • Zentric Inc. ZNTR (14)
  • Zevotek Inc. ZVTK (8)
  • Zinc One Resources Inc. ZZZOF (3)
  • Znomics Inc. ZNOM (3)
  • Newsletter Signup

    Stay ahead of the pack with QualityStocks and receive "The QualityStocks Daily", our summary formatted newsletter containing stock tips from hundreds of online investment newsletters.

    Rotate your device 90° to view site.